Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published May 2014
  • Article
  • Info & Metrics
  • PDF
Loading

NVP-BYL719 PI3Kα Inhibitor and Predictive Modeling of Response

Fritsch et al. Page 1117

Novel targeted therapeutics, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients. Here, Fritsch and colleagues describe the application of the Cancer Cell Line Encyclopedia as a preclinical platform to refine the patient stratification strategy for NVP-BYL719, a novel, potent, and selective PI3Kα-specific inhibitor currently in clinical development. The authors found that PIK3CA mutation was the foremost positive predictor of sensitivity while revealing additional positive and negative associations such as PIK3CA amplification and PTEN mutation, respectively.

Regulation of STAT5 Function by BRD2 in Leukemias

Liu et al. Page 1194

It is known that the transcription factor STAT5 is a potential therapeutic target for hematological malignancies. Bromodomain-containing proteins play an important role in transcriptional regulation. In this study, Liu and colleagues analyzed the interaction between STAT5 and bromodomain-containing proteins and found that the bromodomain family protein BRD2 is an important cofactor for STAT5 transcriptional function. Furthermore, inhibition of BRD2, particularly in combination with specific kinase inhibitors, can induce apoptosis in leukemia cell lines and primary leukemia cells dependent on STAT5, but not in normal hematopoietic cells. These findings suggest a novel rational strategy for treating leukemias and lymphomas driven by constitutive STAT5 activation.

JAK1/JAK2 Inhibition Suppresses Prostate Cancer Metastases

Gu et al. Page 1246

Metastatic prostate cancer is lethal and lacks effective strategies for prevention or treatment, requiring novel therapeutic approaches. Interleukin-6 (IL-6) is a multifunctional cytokine implicated in prostate cancer pathogenesis. In this study, Gu and colleagues investigated the direct functional role of IL-6 in metastatic progression of prostate cancer. IL-6 promoted prostate cancer metastases in vitro and in vivo via Jak2-Stat3 signaling pathway. IL-6–driven metastasis was effectively suppressed by pharmacological targeting of Jak1/2 by Jak1/2 inhibitor AZD1480. Pharmacological Jak1/2 inhibition may provide a novel treatment strategy for advanced prostate cancer.

GALR2-Induced p38 MAPK Promotes Cytokine Secretion and Tumor Angiogenesis

Banerjee and Van Tubergen et al. Page 1323

Cancer therapeutics targeting individual cytokines are ineffective in improving patient survival likely due to overlapping effects between multiple cytokines. Here, Banerjee, Van Tubergen, and colleagues describe a novel angiogenic signaling cascade in squamous cell carcinoma of the head and neck (SCCHN), driven by GALR2, a G protein–coupled receptor. GALR2 promotes p38-MAPK and down-regulates the RNA-degrading protein tristetraprolin, leading to enhanced secretion of proangiogenic cytokines and angiogenesis. Targeting upstream regulators of angiogenesis may be a more effective clinical strategy than modulation of individual cytokines. Therefore, this study indicated that GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.

  • ©2014 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (5)
May 2014
Volume 13, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther May 1 2014 (13) (5) 1019;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther May 1 2014 (13) (5) 1019;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • NVP-BYL719 PI3Kα Inhibitor and Predictive Modeling of Response
    • Regulation of STAT5 Function by BRD2 in Leukemias
    • JAK1/JAK2 Inhibition Suppresses Prostate Cancer Metastases
    • GALR2-Induced p38 MAPK Promotes Cytokine Secretion and Tumor Angiogenesis
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement